Kala Pharmaceuticals Inc.
13F holders, Q1 2026 (March 31)3holders
1new positions
1sold out
$0.17avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Kala Pharmaceuticals Inc. in their 13F filings, unchanged from Q4 2025. 1 opened new positions and 1 sold out. The largest holders were Harbour Investments, Inc. ($26), Cheviot Value Management, LLC ($26) and Parallel Advisors, LLC ($0).
- Company
- Kala Pharmaceuticals Inc.
- Filed as
- KALA BIO INC COM (Q1 2026)
- CUSIP
- 483119103
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $26 |
| Exits | 1 | $394 |
All 13F filers, Q4 2025 → Q1 2026: 150 shares bought and 709 shares sold, net −559 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Harbour Investments, Inc. | 0.00% | New | 150 | $26 |
| Cheviot Value Management, LLC | 0.00% | No change | 153 | $26 |
| Parallel Advisors, LLC | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is KALA PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Kala Pharmaceuticals Inc. the manager owns.